---
category: news
title: "Kiromic Announces FDA IND Submission First-In-Human, AI derived Off-The-Shelf IsoMesothelin Gamma Delta CAR T-cell Therapy, 30 Days Before the End of the Second Quarter"
excerpt: "Kiromic achieves key milestone for this first-in-human Phase 1 clinical trial with a target derived by Kiromicâ€™s AI platform. HOUSTON-- ( BUSINESS WIRE )--Kiromic Biopharma, Inc. (Nasdaq: KRBP), an immuno-oncology target discovery and gene-editing company with a proprietary artificial intelligence neural network platform (Diamond AI) that is used to develop novel oncology therapeutics,"
publishedDateTime: 2021-05-24T15:55:00Z
originalUrl: "https://www.businesswire.com/news/home/20210524005256/en/Kiromic-Announces-FDA-IND-Submission-First-In-Human-AI-derived-Off-The-Shelf-IsoMesothelin-Gamma-Delta-CAR-T-cell-Therapy-30-Days-Before-the-End-of-the-Second-Quarter"
webUrl: "https://www.businesswire.com/news/home/20210524005256/en/Kiromic-Announces-FDA-IND-Submission-First-In-Human-AI-derived-Off-The-Shelf-IsoMesothelin-Gamma-Delta-CAR-T-cell-Therapy-30-Days-Before-the-End-of-the-Second-Quarter"
type: article

provider:
  name: Business Wire
  domain: businesswire.com

topics:
  - AI in Healthcare
  - AI

secured: "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;jUiq0NEfvMfyC/Myr5WNDA=="
---

